Please login to the form below

Not currently logged in
Email:
Password:

Boehringer names new UK MD

Zinta Krumins has been with company for 25 years
Boehringer - Zinta Krumins

Boehringer Ingelheim has named company veteran Zinta Krumins as its new UK and Ireland managing director.

The move is a return to the UK for Krumins who started her Boehringer career at Bracknell as market research manager in 1989, but left to join the company's German business in 1996.

She has since held senior management roles at Boehringer across the globe, including spells as head of human pharma in Denmark, managing director in Turkey and head of prescription medicines and consumer healthcare across the Middle East, Asia and Africa.

Most recently Krumins served at Boehringer's operations covering the Nordic regions, initially as head of prescription medicines and then as the region's managing director.

Krumins commented on her long service with the company: “There is a great working environment at Boehringer Ingelheim and, although it is a very large corporation, my 25-year career path with the company is testament to the fact that it still allows people to command our own destinies”

On her return to the UK she said: “I am delighted to now be back in the UK again, particularly at such an interesting time for our industry.”

She added: “My UK team has been working hard to meet the changing requirements of the evolving NHS and I am confident we are in a good position to strengthen our position as one of the leading companies within the industry.”

13th January 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics